Satellos to Present Four Posters at World Muscle Society Congress

TORONTO, Sept. 15, 2026 /CourierPR/ -- Satellos Bioscience Inc, a clinical-stage drug development company, will present four posters at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan, from September 29 to October 3, 2026. The presentations will focus on the company's drug candidate, Forazapadin (SAT-3247), which is being developed to treat degenerative muscle diseases, including Duchenne Muscular Dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).

Connolly, MD, Chief of the Division of Neurology at Nationwide Children's Hospital. This study aims to compare different doses of Forazapadin and explore its potential efficacy in boys with DMD.

Connolly. This open-label study will assess the long-term safety and efficacy of Forazapadin in adult participants with DMD.

This poster will discuss the translation of preclinical findings to human studies, focusing on the quantification of muscle degeneration and the response to disease-modifying treatments.

This study will evaluate the safety, tolerability, and long-term efficacy of Forazapadin in individuals with FSHD.

Forazapadin is a proprietary, oral, small molecule drug candidate developed by Satellos to regenerate skeletal muscle lost in DMD and other degenerative muscle diseases. The drug targets AAK1, a key protein that supports muscle regeneration. Satellos is advancing Forazapadin as a potential treatment for DMD, with ongoing Phase 2 clinical studies including BASECAMP and TRAILHEAD. The company plans to submit an Investigational New Drug application and begin clinical research to investigate the use of Forazapadin in individuals with FSHD in the second half of 2026.

The posters will be available in the Presentations and Publications section of Satellos' website, providing further details on the company's research and development efforts.